Filing Details

Accession Number:
0001593968-20-002228
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-20 16:31:45
Reporting Period:
2020-11-18
Accepted Time:
2020-11-20 16:31:45
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
887247 Adamis Pharmaceuticals Corp ADMP Pharmaceutical Preparations (2834) 820429727
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1461753 J. David Marguglio C/O Adamis Pharmaceuticals Corporation
11682 El Camino Real, Ste 300
San Diego CA 92130-
Svp And Chief Business Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-11-18 8,532 $0.41 322,264 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 5,884 Indirect By D. Marguglio as custodian for children
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. The shares were sold to satisfy the withholding and tax obligations relating to the issuance of shares upon the vesting of RSUs previously granted to the reporting person.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4025 to $0.408, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, anysecurity holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. Includes shares of common stock beneficially owned and shares of common stock issuable upon vesting of restricted stock units previously reported in Table 1 of Form 4.